SciSparc's subsidiary MitoCareX approved for acquisition by N2OFF shareholders; shares up 29%
2025-09-29 16:27:28 ET
SciSparc Ltd. ( NASDAQ: SPRC ) announced that N2OFF ( NASDAQ: NITO ) shareholders approved the acquisition of MitoCareX, SciSparc’s majority-owned cancer therapy subsidiary, on September 25, 2025.
Upon closing, MitoCareX will become a wholly owned subsidiary of N2OFF, focused on mitochondrial protein-targeted therapies for hard-to-treat cancers.
Deal terms include $700K cash to SciSparc and 40% of N2OFF’s fully diluted stock to MitoCareX shareholders, with future milestone-based stock issuances and 30% share in financing proceeds (capped at $1.6M).
N2OFF has committed to a $1M initial investment and ongoing support for two years post-closing.
Final closing is targeted for early October 2025.
SPRC shares up 28.7% post-market on Monday.
Source: Press release
Read the full article on Seeking Alpha
For further details see:
SciSparc’s subsidiary MitoCareX approved for acquisition by N2OFF shareholders; shares up 29%
NASDAQ: NITO
NITO Trading
25.83% G/L:
$1.12 Last:
900,589 Volume:
$0.945 Open:
